Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of SYS6026 combination therapy in HPV16/18-associated advanced solid tumors
CTR20262308Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of SYS6026 in human papillomavirus-associated cancer, Cervical Cancer (CC), anal cancer, Vulval carcinoma, vaginal cancer, sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Jun 2026; status: active.
02
Drugs
SYS6026
03
Conditions
human papillomavirus-associated cancerCervical Cancer (CC)anal cancerVulval carcinomavaginal cancer
Beyond the preview
Go deeper on CTR20262308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262308.